Protagenic Therapeutics Statistics
Share Statistics
Protagenic Therapeutics has 7.53M
shares outstanding. The number of shares has increased by 62.65%
in one year.
| Shares Outstanding | 7.53M |
| Shares Change (YoY) | 62.65% |
| Shares Change (QoQ) | 1.37% |
| Owned by Institutions (%) | 14.16% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14,305 |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 295.43K, so 3.93% of the outstanding
shares have been sold short.
| Short Interest | 295.43K |
| Short % of Shares Out | 3.93% |
| Short % of Float | 4.48% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.43 and the forward
PE ratio is null.
Protagenic Therapeutics's PEG ratio is
0.25.
| PE Ratio | -0.43 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.37 |
| P/FCF Ratio | -0.57 |
| PEG Ratio | 0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Protagenic Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2,
with a Debt / Equity ratio of 0.
| Current Ratio | 2 |
| Quick Ratio | 2 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-5,525,344 |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.61% in the
last 52 weeks. The beta is 0.35, so Protagenic Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -82.61% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.5 |
| Relative Strength Index (RSI) | 47.89 |
| Average Volume (20 Days) | 5,417,126 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.7M |
| Net Income | -5.53M |
| EBITDA | -5.7M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.13 |
Full Income StatementBalance Sheet
The company has 1.84M in cash and 0 in
debt, giving a net cash position of 1.84M.
| Cash & Cash Equivalents | 1.84M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -36.3M |
| Total Assets | 1.96M |
| Working Capital | 940.11K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -4.22M
and capital expenditures 0, giving a free cash flow of -4.22M.
| Operating Cash Flow | -4.22M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.22M |
| FCF Per Share | -0.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
